KORU Medical Systems, Inc.KRMD

KorU Medical Systems Inc. (KRMD) is a small-cap medical device outfit whose website greets visitors with splash pages of the Freedom60® infusion system, FreedomEDGE® portable pumps, and High-Flo™ subcutaneous safety needles-each dressed up as the path to “freedom” for patients and clinicians alike. Beneath the marketing gloss, the company’s most recent 10-Q for the quarter ended 31 March 2026 shows revenues of $11.8 million, a 22.1 % jump from the same stretch in 2025, yet still a figure that would sit comfortably in the rounding bin for most med-tech giants. The same filing records a net loss attributable to parent of $807,078, turning the “freedom” slogan into a punchline when the accounts arrive in the post. (source: KRMD 10-Q, https://www.sec.gov/Archives/edgar/data/704440/000116169726000108/form_10-q.htm)

The Freedom60® system is designed for subcutaneous infusions and pitched as “simple, robust, and accident-safe,” with the FreedomEDGE® pump marketed as an “easy-to-use, portable infusion pump” for small-dose or recurring therapies. The High-Flo™ safety needles are described as “back-cut to minimize scarring and pain.” Product pages do not, however, disclose how much of the $11.8 million revenue is flowing from which device or geography, nor do they quantify the gross margin on each Freedom60® or FreedomEDGE® unit. The company’s own filings show the Freedom60® is cleared for use with Hizentra® and Xembify®-immunoglobulin products from CSL Behring and Grifols-yet the 10-Q does not parse how much of the revenue surge is driven by these specific therapies versus other infusions. (source: Freedom60® product page, https://www.korumedical.com/products/freedom60; FreedomEDGE® product page, https://www.korumedical.com/products/freedomedge; High-Flo™ product page, https://www.korumedical.com/products/high-flo-needle-sets)

Cash and cash equivalents stood at $8.8 million at 31 March 2026, while operating cash flow for the quarter was a modest $14,663-numbers that place the company’s liquidity closer to a lean biotech start-up than a scaled med-tech player. Inventory climbed $798,173 to $4.5 million, a build that could signal either supply-chain prudence or a sales-force struggling to clear stock. Research and development expense was $1.3 million for the quarter, above the headline net loss, underscoring that the company is still funding product iteration rather than harvesting profits. Diluted loss per share was two cents for the quarter, with 46.4 million diluted shares outstanding. Assets totalled $28.6 million and liabilities $11.7 million, leaving shareholders’ equity at $16.9 million-numbers that do not scream “buy-the-dip” territory. (source: KRMD 10-Q, https://www.sec.gov/Archives/edgar/data/704440/000116169726000108/form_10-q.htm)

The company’s latest SEC filings show a flurry of insider transactions in early July 2026, with six Form 4s filed within a week-conduct that is disclosed but not explained. The 8-K filed 30 June 2026 also announces an amended manufacturing and supply agreement with Command Medical Products LLC, framed as a routine update yet arriving one quarter after the company posted its largest revenue quarter in years. The 8-K does not quantify any financial terms of the amendment, leaving investors to wonder whether the pact secures volume discounts, minimum purchase commitments, or exclusive supply rights. (source: KRMD 8-K, https://www.sec.gov/Archives/edgar/data/704440/000116169726000139/form_8-k.htm; KRMD 4/As and 4s, https://www.sec.gov/Archives/edgar/browse/?CIK=704440)

For readers seeking a chart route, the company does not publish a dedicated investor-relations graphics pack. Public market data aggregators show KRMD listed on the OTCQB tier with thin liquidity, a pattern consistent with small-cap med-tech names that lack analyst coverage and institutional sponsorship. The absence of a formal investor-relations site and the reliance on OTCQB plumbing mean that price discovery is more likely to reflect order-flow than fundamentals, a reality that is itself a material risk for any holder seeking to exit. (source: OTC Markets KRMD page, https://www.otcmarkets.com/stock/KRMD/profile)